Clinical Trial: Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Study Type: OBSERVATIONAL
Official Title: Impact of Alirocumab on Cardiovascular Events in Individuals With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
Brief Summary:
The objective of this study is to evaluate ischemic event rates among individuals with established atherosclerotic cardiovascular disease without prior acute ischemic events, comparing those treated with alirocumab versus those receiving no proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) therapy. The study will leverage observational data reflective of routine clinical practice and will apply contemporary approaches in target trial emulation and causal inference to estimate treatment effects.
Read more